GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Short Interest

PCI Biotech Holding ASA (OSL:PCIB) Short Interest


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PCI Biotech Holding ASA's Short Interest

For the Biotechnology subindustry, PCI Biotech Holding ASA's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Short Interest distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Short Interest falls into.


;
;

PCI Biotech Holding ASA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Short Interest
Comparable Companies
OSL:CRNA OSL:BGBIO OSL:ABS OSL:EXTX OSL:SOFTX OSL:ONCIN OSL:ABTEC OSL:ZLNA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX
Traded in Other Exchanges
0JGL:UK
Address
Ullernchausseen 64, Oslo, NOR, N-0379
Website
https://www.pcibiotech.com
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines